The role of biomarkers in management of interstitial lung disease: implications of biomarkers derived from type II pneumocytes

T. Nukiwa

Source: Eur Respir Mon; 2009: 46: 47–66
Disease area: Interstitial lung diseases

PDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
T. Nukiwa. The role of biomarkers in management of interstitial lung disease: implications of biomarkers derived from type II pneumocytes. Eur Respir Mon; 2009: 46: 47–66

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
The role of cell lines in modelling the type II pneumocyte in interstitial lung disease
Source: Virtual Congress 2020 – Human ex vivo models of interstitial lung disease
Year: 2020

Identifying serum molecular biomarkers that distinguish emphysema and early fibrotic interstitial lung disease.
Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia
Year: 2021

The role of calcium metabolism assessment in the clinical setting of interstitial lung diseases
Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis
Year: 2021

Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities
Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options
Year: 2021

A novel serum biomarker of type XXVIII collagen turnover is elevated in lung cancer but not in COPD
Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer
Year: 2020

Identifying pulmonary hypertension in newly recognized interstitial lung diseases – a role of new scoring system
Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Year: 2020

Evidence of type II pneumocyte apoptosis in the murine model of Hermansky-Pudlak-syndrome associated interstitial pneumonia
Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies
Year: 2008

The role of macrophages in interstitial lung diseases
Source: Eur Respir Rev, 26 (145) 170009; 10.1183/16000617.0009-2017
Year: 2017

The effectiveness of pulmonary rehabilitation in interstitial lung diseases in terms of functional markers
Source: International Congress 2018 – What’s hot in rehabilitation in COPD and interstitial lung disease (ILD)?
Year: 2018

Different definitions of pulmonary hypertension in interstitial lung disease: a prognostic evaluation.
Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases
Year: 2020

Circulating fibrocytes and collagen turnover products in UIP: marker of disease activity and prognostic tool?
Source: Eur Respir J 2007; 30: Suppl. 51, 118s
Year: 2007

Circulating fibrocytes as prognostic biomarkers of autoimmune interstitial lung disease
Source: ERJ Open Res, 6 (4) 00481-2020; 10.1183/23120541.00481-2020
Year: 2020

Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes
Source: Eur Respir J, 55 (4) 2000105; 10.1183/13993003.00105-2020
Year: 2020

The use of non-invasive inflammatory markers to predict presence, severity and stability of cystic fibrosis lung disease
Source: Eur Respir J 2006; 28: Suppl. 50, 327s
Year: 2006

Progress in the pathology of diffuse lung disease in infancy: changing concepts and diagnostic challenges
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 978-1-904097-51-8, page=21
Year: 2007

Are risk predicting models useful for estimating survival in rheumatoid arthritis-associated interstitial lung disease?
Source: International Congress 2016 – Connective tissue disorders
Year: 2016

Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival
Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis
Year: 2019

Issues other than tissue: non-invasive biomarkers of early stage lung cancer
Source: Virtual Congress 2020 – Will the pulmonologist still play a role in the management of screen-detected pulmonary nodules?
Year: 2020

Transplantation of alveolar type II cells in pulmonary fibrosis: experimental studies, MSC in IPF trials
Source: International Congress 2014 – Targeting lung fibrosis: from bench to bedside
Year: 2014

alpha-v-beta-6 integrin may be a potential prognostic biomarker in interstitial lung disease
Source: Eur Respir J 2015; 46: 486-494
Year: 2015